Table 1.
Baseline characteristics of participants according to the tertiles of AGR (n = 196). Values are mean ± SD or n (%)
| Characteristics | AGR (Total) | AGR tertile | p-value | ||
|---|---|---|---|---|---|
| Low (0.70–1.34) | Middle (1.35–1.65) | High (1.65–2.45) | |||
| No. of participants | 196 | 65 | 64 | 67 | |
| Age, years | 60.44 ± 10.14 | 62.78 ± 9.55 | 61.86 ± 9.31 | 56.82 ± 10.56 | 0.001 |
| Male | 126 (64.29%) | 45 (69.23%) | 37 (57.81%) | 44 (65.67%) | 0.384 |
| Never smoker | 127 (64.80%) | 38 (58.46%) | 45 (70.31%) | 44 (65.67%) | 0.364 |
| Hypertension | 66 (33.67%) | 22 (33.85%) | 25 (39.06%) | 19 (28.36%) | 0.432 |
| Leukocyte, 109/L | 7.07 ± 2.57 | 7.70 ± 2.79 | 7.05 ± 2.17 | 6.48 ± 2.60 | 0.023 |
| Neutrophil, 109/L | 4.97 ± 2.21 | 5.35 ± 2.40 | 4.99 ± 1.91 | 4.58 ± 2.24 | 0.132 |
| Lymphocyte, 109/L | 1.31 ± 0.55 | 1.42 ± 0.56 | 1.33 ± 0.55 | 1.19 ± 0.54 | 0.055 |
| Platelets, 109/L | 256.67 ± 98.46 | 292.65 ± 109.65 | 258.56 ± 98.37 | 219.97 ± 71.43 | < 0.001 |
| Albumin, g/L | 41.84 ± 4.65 | 38.15 ± 4.66 | 43.37 ± 3.56 | 43.98 ± 3.23 | < 0.001 |
| Globulin, g/L | 28.51 ± 4.97 | 33.18 ± 3.84 | 28.97 ± 2.56 | 23.52 ± 2.33 | < 0.001 |
| ALK rearrangement | 0.395 | ||||
| No | 136 (69.39%) | 41 (63.08%) | 45 (70.31%) | 50 (74.63%) | |
| Yes | 3 (1.53%) | 1 (1.54%) | 2 (3.12%) | 0 (0.00%) | |
| Unknown | 57 (29.08%) | 23 (35.38%) | 17 (26.56%) | 17 (25.37%) | |
| EGFR mutation | 0.200 | ||||
| No | 83 (42.35%) | 27 (41.54%) | 31 (48.44%) | 25 (37.31%) | |
| Yes | 57 (29.08%) | 15 (23.08%) | 16 (25.00%) | 26 (38.81%) | |
| Unknown | 56 (28.57%) | 23 (35.38%) | 17 (26.56%) | 16 (23.88%) | |
| Histology | 0.033 | ||||
| Adenocarcinoma | 124 (63.27%) | 49 (75.38%) | 42 (65.62%) | 33 (49.25%) | |
| Squamous cell carcinoma | 47 (23.98%) | 9 (13.85%) | 15 (23.44%) | 23 (34.33%) | |
| Others | 25 (12.76%) | 7 (10.77%) | 7 (10.94%) | 11 (16.42%) | |
| Tumor stage | 0.853 | ||||
| III | 30 (15.31%) | 11 (16.92%) | 10 (15.62%) | 9 (13.43%) | |
| IV | 166 (84.69%) | 54 (83.08%) | 54 (84.38%) | 58 (86.57%) | |
| ECOG PS score | 0.348 | ||||
| 0 | 136 (69.39%) | 41 (63.08%) | 45 (70.31%) | 50 (74.63%) | |
| 1 | 60 (30.61%) | 24 (36.92%) | 19 (29.69%) | 17 (25.37%) | |
| Number of metastases | 0.955 | ||||
| < 3 | 153 (78.06%) | 50 (76.92%) | 50 (78.12%) | 53 (79.10%) | |
| ≥ 3 | 43 (21.94%) | 15 (23.08%) | 14 (21.88%) | 14 (20.90%) | |
| Number of previous treatment lines | 0.070 | ||||
| < 3 | 107 (54.59%) | 40 (61.54%) | 38 (59.38%) | 29 (43.28%) | |
| ≥ 3 | 89 (45.41%) | 25 (38.46%) | 26 (40.62%) | 38 (56.72%) | |
| Number of previous chemotherapy lines | 0.029 | ||||
| ≤ 2 | 153 (78.06%) | 54 (83.08%) | 54 (84.38%) | 45 (67.16%) | |
| > 2 | 43 (21.94%) | 11 (16.92%) | 10 (15.62%) | 22 (32.84%) | |
| Previous targeted therapy | 69 (35.20%) | 21 (32.31%) | 19 (29.69%) | 29 (43.28%) | 0.222 |
| Previous radiotherapy | 35 (17.86%) | 12 (18.46%) | 9 (14.06%) | 14 (20.90%) | 0.587 |
| Previous immunotherapy | 32 (16.33%) | 11 (16.92%) | 10 (15.62%) | 11 (16.42%) | 0.980 |
| Anlotinib monotherapy | 156 (79.59%) | 53 (81.54%) | 52 (81.25%) | 51 (76.12%) | 0.685 |
*Continuous variable was obtained by Kruskal-Wallis rank sum test. If the count variable had a theoretical number < 10, the probability was calculated accurately using Fisher’s exact test